CONNECT WITH US
HealthTech

HealthTech

Blood test may reveal which lymphoma patients will respond to immunotherapy

Medical Xpress logo

Published on

Add as a preferred source on Google
Blood test may reveal which lymphoma patients will respond to immunotherapy

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

Cornell engineers and Dana-Farber oncologists found that RNA floating in the plasma carries a signature of a lymphoma tumor's surroundings, one that tracked with whether patients were still in remission a year later.

Of 91 lymphoma patients who received a powerful cell therapy at Dana-Farber Cancer Institute, those whose blood carried a particular gene expression signature before treatment were far less likely to see their cancer progress. Patients with high scores on that signature had an 80% lower risk of progression than those with low scores, according to a new study from Cornell and Dana-Farber. The research was published Nov. 18 in the journal Cell Reports Medicine.

The genetic signature comes from cell-free RNA, fragments of genetic material shed by cells into the bloodstream. The researchers say it offers a glimpse of the tumor's local environment without the need for a biopsy.

The research addresses a deficit in a current therapy for an aggressive blood cancer known as large B-cell lymphoma. Anti-CD19 CAR T-cell therapy, in which a patient's own immune cells are engineered to hunt cancer, has transformed care for people with large B-cell lymphoma. But nearly half of patients either fail to respond or relapse within a year. Until now, doctors have had few reliable ways to predict who will do well.

"CAR T-cell therapy is one of the major breakthroughs of the past couple of decades, but not every patient responds," said Iwijn De Vlaminck, professor in the Meinig School of Biomedical Engineering in the Cornell Duffield College of Engineering, who led the research.


Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.